Pharmacology & ToxicologyNature CommunicationsPeer-reviewed
Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity
Xin Yu, Dong Lu, Xiaoli Qi…·Jin Wang
This paper develops a first-in-class RIPK1 degrader, LD4172, which enhances antitumor immunity by promoting immunogenic cell death and sensitizing tumors to anti-PD1 therapy.
43 citationstop 3%